Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome

• NASDAQ: $VNDA
• Notified: $11.38
• 07:01 EDT